Inmune Bio Inc Stock Price, News & Analysis

INmune Bio (NASDAQ: INMB) has initiated patient enrollment for a crucial six-month Phase 2 trial assessing XPro1595 in patients with mild Alzheimer's disease (AD). This multicenter, randomized, placebo-controlled study aims to evaluate cognitive function and improvement in biomarkers associated with neuroinflammation. Following positive results from the Phase 1 trial, which showed a reduction in neuroinflammation and improvements in neurorepair biomarkers, the company anticipates enrolling 201 patients across the U.S., Australia, and Canada.

INmune Bio (NASDAQ: INMB) has announced significant findings regarding its product INB03 for treating trastuzumab-resistant MUC4 HER2+ breast cancer. Data from animal models indicate that INB03 effectively decreases MUC4 expression, reversing resistance to trastuzumab and tyrosine kinase inhibitors while enhancing an active tumor microenvironment. This research was presented at the American Association of Cancer Research Annual Meeting. Previous studies reveal MUC4 expression correlates with poorer survival outcomes. INB03 is poised for further clinical testing.

INmune Bio (NASDAQ: INMB) presented significant findings regarding its NK cell therapy, INKmune™, during the NK Cells in Solid Tumors workshop at the Innate Killer Summit. Dr. Mark Lowdell, the CSO, emphasized INKmune™'s unique ability to enhance NK cell survival and function in hostile tumor environments by upregulating mitochondrial proteins and nutrient receptors. Clinical data suggests that INKmune-primed NK cells can persist in the body for over 15 weeks, raising the potential for synergistic use with adoptive NK therapies. The company continues to explore collaborations for future clinical trials.

INmune Bio, Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Dr. Lowdell, will lead a workshop at the 7th Innate Killer Summit in San Diego from March 30 to April 1, focusing on natural killer (NK) cells in treating solid tumors. The workshop aims to address challenges faced in NK cell therapies. Additionally, INmune will present case studies on INKmune™ showing promising results in three patients, including no side effects and improved disease outcomes. The company continues to advance its clinical trials targeting the innate immune system.

INmune Bio, Inc. (NASDAQ: INMB) recently presented at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's diseases held from March 15-20 in Barcelona, Spain. The company emphasized the growing importance of targeting neuroinflammation in Alzheimer's Disease (AD) treatments, particularly with its Xpro™ therapy. Notable findings include improved synaptic function indicators post-treatment and the use of white matter pathology as a biomarker for predicting AD progression. CEO R.J. Tesi highlighted the significance of these insights in advancing clinical trials and drug development strategies.

INmune Bio (NASDAQ: INMB) presented nine data pieces at the AD/PD^™ 2022 International Conference, held from March 15-20 in Barcelona, focusing on XPro™'s potential in treating Alzheimer’s Disease. This marks the first exposure for many EU and UK clinicians to INmune Bio’s approach targeting neuroinflammation. Key presentations include MRI measures from the Phase 1 trial and insights for Phase 2 trial design. The data emphasizes XPro™’s versatility and novel biomarkers being utilized in clinical strategies.

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced that its CEO, RJ Tesi, MD, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Dr. Tesi's corporate overview is scheduled for March 16, 2022, at 11:20am ET. Additionally, he will join a fireside chat at the 2022 Maxim Group Virtual Growth Conference on March 30, 2022, at 11:00am ET. INmune Bio is focused on treatments leveraging the immune system to combat diseases like cancer and Alzheimer's. Visit www.inmunebio.com for more information.

INmune Bio, Inc. (NASDAQ: INMB) announced positive results from ongoing clinical trials, including a Phase I trial using INKmuneTM for high-risk myelodysplastic syndrome (MDS) that showed a 60% activation rate of NK cells in a patient after therapy. The company also opened a Phase II trial for treating mild Alzheimer's disease (AD) with XProTM, expecting data in 2023. Financially, INMB reported a net loss of $30.3 million for 2021 but had cash reserves of approximately $74.8 million as of December 31, 2021. Upcoming milestones include expansion of clinical trial sites and additional patient enrollments.

INmune Bio (NASDAQ: INMB) will host a conference call on March 3, 2022, at 4:30 PM ET, to discuss its fourth-quarter results for 2021 and provide a corporate update. The call can be accessed via phone or through a live audio webcast. Participants are encouraged to join several minutes early. A transcript and a replay will be available shortly after the call. INmune Bio is focused on developing therapies that leverage the innate immune system to tackle diseases, with ongoing clinical trials involving products like INB03 and XPro.